{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T16:04:24Z","timestamp":1784649864978,"version":"3.55.0"},"reference-count":34,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Sarcomatoid carcinoma of the upper urinary tract (SCUT) is a rare and aggressive malignancy. Due to its rarity, the molecular landscape and the prevalence of potentially targetable alterations are poorly characterized. We aimed to compare the clinical, pathological, and genomic profiles of SCUT and upper tract urothelial carcinoma (UTUC). Methods: We leveraged the Tempus Lens clinically annotated genomic dataset to extract clinicopathologic and somatic genomic alteration data from patients with UTUC and SCUT. Patients with any-stage disease who underwent either blood- or tissue-based next-generation sequencing were included. Baseline clinical and demographic characteristics were summarized using descriptive statistics. Comparisons between groups were performed using Wilcoxon rank-sum test for continuous variables and the Chi-square test\/Fisher\u2019s exact test for categorical variables. Mutational frequencies and pairwise comparisons were performed to assess significant differences between groups. Results: In total, 1721 patients were included, of which 1600 (93%) had UTUC and 121 (7%) had SCUT. Patients with SCUT were younger at diagnosis, 61 years (interquartile range (IQR) 54, 70), compared to UTUC, 71 years (IQR 64, 77) (p &lt; 0.001), and were more likely to have node-positive disease at presentation (all p &lt; 0.001). SCUT patients were more likely to show visceral metastases to the lung (44% vs. 21%), bone (31% vs. 17%), and brain (7% vs. 1%), compared to UTUC (all p &lt; 0.05). Among SCUT patients, the most common genomic alterations were TERT (30%), TP53 (29%), NF2 (19%), PTEN (13%), SETD2 (12%), PBRM1 (12%), and BAP1 (8%). Among UTUC patients, the most common were TERT (52%), TP53 (52%), KMT2D (30%), FGFR3 (25%), ARID1A (20%), and KDM6A (18%). Compared to UTUC, SCUT was significantly enriched with NF2, SETD2, PBRM1, PTEN, and BAP1 (all p &lt; 0.05). SCUT was depleted in FGFR3 (0% vs. 25%) and FGF4 (0% vs. 8%) mutations compared to UTUC (both p &lt; 0.05). Targetable alterations were observed in SCUT, including NF2, SETD2, and PTEN. Conclusion: Compared with UTUC, SCUT exhibits a more aggressive clinical and genomic phenotype, characterized by enrichment in NF2, SETD2, PBRM1, and PTEN. These findings underscore the divergent molecular landscape of SCUT and highlight potentially targetable genomic alterations.<\/jats:p>","DOI":"10.3390\/cancers18142352","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:17:52Z","timestamp":1784647072000},"page":"2352","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genomic Characterization of Urothelial Carcinoma and Sarcomatoid Carcinoma of the Upper Urinary Tract"],"prefix":"10.3390","volume":"18","author":[{"given":"Salvador","family":"Jaime-Casas","sequence":"first","affiliation":[{"name":"Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Salgia","sequence":"additional","affiliation":[{"name":"Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2181-8405","authenticated-orcid":false,"given":"Miguel","family":"Zugman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3521-6496","authenticated-orcid":false,"given":"Vitor","family":"Goes","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Moradi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koral","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Winayak","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Barragan-Carrillo","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Cancerologia (INCAN), Mexico City 14080, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jadon","family":"Fann","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6646-7644","authenticated-orcid":false,"given":"George","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8026-9514","authenticated-orcid":false,"given":"Benjamin","family":"Mercier","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5423-9821","authenticated-orcid":false,"given":"Daniela V.","family":"Castro","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazli","family":"Dizman","sequence":"additional","affiliation":[{"name":"M.D. Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5205-4527","authenticated-orcid":false,"given":"Alexander","family":"Chehrazi-Raffle","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5990-298X","authenticated-orcid":false,"given":"Tanya","family":"Dorff","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley","family":"Yip","sequence":"additional","affiliation":[{"name":"Division of Urology and Urologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta K.","family":"Pal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00428-020-02745-4","article-title":"Clinicopathologic Analysis of Upper Urinary Tract Carcinoma with Variant Histology","volume":"477","author":"Rolim","year":"2020","journal-title":"Virchows Arch."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ajur.2022.05.009","article-title":"Genitourinary Manifestations of Lynch Syndrome in the Urological Practice","volume":"9","author":"Lonati","year":"2022","journal-title":"Asian J. Urol."},{"key":"ref_3","first-page":"528","article-title":"Urothelial Carcinoma: Perioperative Considerations from Top to Bottom","volume":"75","author":"Yip","year":"2025","journal-title":"CA A Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.euo.2021.11.001","article-title":"Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology\u2014Young Academic Urologists and the Global Society of Rare Genitourinary Tumors","volume":"5","author":"Lonati","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1038\/s41467-024-46320-w","article-title":"The Evolution of Metastatic Upper Tract Urothelial Carcinoma through Genomic-Transcriptomic and Single-Cell Protein Markers Analysis","volume":"15","author":"Ohara","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_6","first-page":"48","article-title":"Implications of Micropapillary Urothelial Carcinoma Variant on Prognosis Following Radical Cystectomy: A Multi-Institutional Investigation","volume":"37","author":"Mitra","year":"2019","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.eururo.2018.11.052","article-title":"Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis of Disease Characteristics and Treatment Outcomes","volume":"75","author":"Abufaraj","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1002\/cncr.30907","article-title":"Neoadjuvant Chemotherapy Prior to Radical Cystectomy for Muscle-invasive Bladder Cancer with Variant Histology","volume":"123","author":"Vetterlein","year":"2017","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.humpath.2017.05.001","article-title":"Variant Morphology in Upper Urinary Tract Urothelial Carcinoma: A 14-Year Case Series of Biopsy and Resection Specimens","volume":"65","author":"Hayashi","year":"2017","journal-title":"Hum. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/JU.0000000000002799","article-title":"Survival Impact of Variant Histology Diagnosis in Upper Tract Urothelial Carcinoma","volume":"208","author":"Nogueira","year":"2022","journal-title":"J. Urol."},{"key":"ref_11","first-page":"826","article-title":"Morphologic and Genomic Characterization of Urothelial to Sarcomatoid Transition in Muscle-Invasive Bladder Cancer","volume":"37","author":"Genitsch","year":"2019","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1038\/modpathol.2009.26","article-title":"Histological Variants of Urothelial Carcinoma: Diagnostic, Therapeutic and Prognostic Implications","volume":"22","author":"Amin","year":"2009","journal-title":"Mod. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"11702","DOI":"10.1038\/s41598-017-11291-0","article-title":"Comprehensive Multiregional Analysis of Molecular Heterogeneity in Bladder Cancer","volume":"7","author":"Thomsen","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.humpath.2008.07.003","article-title":"Sarcomatoid Carcinoma of the Upper Urinary Tract: Clinical Outcome and Molecular Characterization","volume":"40","author":"Wang","year":"2009","journal-title":"Hum. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2022.40.6_suppl.571","article-title":"Urothelial Carcinoma with Sarcomatoid Variant: A Preliminary Study of Clinical and Pathological Features","volume":"40","author":"Sirgiovanni","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41698-021-00202-2","article-title":"Validation of a Liquid Biopsy Assay with Molecular and Clinical Profiling of Circulating Tumor DNA","volume":"5","author":"Finkle","year":"2021","journal-title":"npj Precis. Onc."},{"key":"ref_17","first-page":"e2500291","article-title":"Validation of a Composite Mortality End Point in a Large Clinicogenomic Real-World Database of Patients With Advanced Cancer","volume":"10","author":"Kapilivsky","year":"2026","journal-title":"JCO Clin. Cancer Inf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"oyag123","DOI":"10.1093\/oncolo\/oyag123","article-title":"Concurrent Tissue and Circulating Tumor DNA Analysis in Renal Cell Carcinoma: Insights from a Multimodal Database","volume":"31","author":"Jani","year":"2026","journal-title":"Oncologist"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.18632\/oncotarget.26797","article-title":"Clinical Validation of the Tempus xT Next-Generation Targeted Oncology Sequencing Assay","volume":"10","author":"Beaubier","year":"2019","journal-title":"Oncotarget"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"25826","DOI":"10.18632\/oncotarget.25381","article-title":"Clinical Validation of the Tempus xO Assay","volume":"9","author":"Beaubier","year":"2018","journal-title":"Oncotarget"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.29245\/2578-2967\/2020\/2.1178","article-title":"Sarcomatoid Transformation in Carcinomas: Is Precision Medicine the Answer?","volume":"4","author":"Arshi","year":"2020","journal-title":"J. Cancer Treat. Diagn."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.euf.2024.05.015","article-title":"What About Variant Histologies in Bladder Cancer?","volume":"10","author":"Day","year":"2024","journal-title":"Eur. Urol. Focus"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.path.2022.07.003","article-title":"Urothelial Carcinoma","volume":"15","author":"Gandhi","year":"2022","journal-title":"Surg. Pathol. Clin."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3892\/ol.2023.13690","article-title":"Prognostic Value of the Sarcomatoid Component in Bladder Cancer: A Propensity Score Matching Study","volume":"25","author":"Liu","year":"2023","journal-title":"Oncol. Lett."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00345-015-1584-6","article-title":"Molecular Profile of Urothelial Carcinoma of the Upper Urinary Tract: Are Pelvicalyceal and Ureteral Tumors Different?","volume":"34","author":"Krabbe","year":"2016","journal-title":"World J. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ccell.2021.05.008","article-title":"Molecular Classification and Diagnostics of Upper Urinary Tract Urothelial Carcinoma","volume":"39","author":"Fujii","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.urology.2005.01.019","article-title":"Microsatellite Instability as Predictor of Survival in Patients with Invasive Upper Urinary Tract Transitional Cell Carcinoma","volume":"65","author":"Fromont","year":"2005","journal-title":"Urology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1056\/NEJMoa022289","article-title":"Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer","volume":"349","author":"Ribic","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized Phase III KEYNOTE-045 Trial of Pembrolizumab versus Paclitaxel, Docetaxel, or Vinflunine in Recurrent Advanced Urothelial Cancer: Results of >2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"102179","DOI":"10.1016\/j.clgc.2024.102179","article-title":"Metastatic Tropism in Urothelial Carcinoma With Variant Histology: A Comprehensive NCDB Analysis","volume":"22","author":"Drouaud","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.juro.2012.04.009","article-title":"Impact of Histological Variants on Clinical Outcomes of Patients with Upper Urinary Tract Urothelial Carcinoma","volume":"188","author":"Rink","year":"2012","journal-title":"J. Urol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.juro.2007.03.033","article-title":"Squamous Cell Carcinoma of the Renal Pelvis and Ureter: Incidence, Symptoms, Treatment and Outcome","volume":"178","author":"Lele","year":"2007","journal-title":"J. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.18632\/oncotarget.1829","article-title":"TERT Promoter Mutations in Renal Cell Carcinomas and Upper Tract Urothelial Carcinomas","volume":"5","author":"Wang","year":"2014","journal-title":"Oncotarget"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2023.41.6_suppl.558","article-title":"Characterizing the Immune Phenotype of FGFR3 Mutated Upper Tract Urothelial Carcinoma (UTUC) Using Single-Cell (Sc)RNA-Sequencing (Seq)","volume":"41","author":"Katims","year":"2023","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2352\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:25:21Z","timestamp":1784647521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":34,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18142352"],"URL":"https:\/\/doi.org\/10.3390\/cancers18142352","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]}}}